|
Families of SMA has Funded the Following Research for the Paratek Program: 1) In 2004, to Dr. Adrian Krainer at Cold Spring Harbor Lab for $20,000 for "In Vtiro Splicing Assay Testing of Small Molecules". 2) In 2005, to Dr. Adrian Krainer at Cold Spring Harbor Lab for $13,333 for "In Vitro Splicing Assay Testing of Small Molecules". 3) In 2006, to Paratek Pharmaceuticals for $402,500 for "Medicinal Chemistry and Lead Optimization of Tetracycline-Derivatives". 4) In 2006, to Dr. Michelle Hastings at Cold Spring Harbor Lab for $131,893 for "Characterization of Small-Molecule Moderators of SMN2 Exon 7 Splicing". 5) In 2006, to Cold Spring Harbor Lab for $56,500 for "Assessment of Tetracycline Compounds in In Vitro Splicing Assays and for SMN Expression". 6) In 2007, to Paratek Pharmaceuticals for $392,000 for ""Medicinal Chemistry and Lead Optimization of Tetracycline-Derivatives". 7) In 2007, to Dr. Adrian Krainer at Cold Spring Harbor Lab for $70,444 for ""Assessment of Tetracycline Compounds in In Vitro Splicing Assays and for SMN Expression". 8) In 2007, to Dr. Michelle Hastings at Rosalind Franklin University for $31,280 for "Characterization of Small-Molecule Moderators of SMN2 Exon 7 Splicing". 9) In 2008, to Paratek Pharmaceuticals for $526,750 for ""Medicinal Chemistry and Lead Optimization of Tetracycline-Derivatives". 10) In 2008, to Dr. Adrian Krainer at Cold Spring Harbor Lab for $70,000 for "Assessment of Tetracycline Compounds in In Vitro Splicing Assays and for SMN Expression". 11) In 2008, to Dr. Michelle Hastings at Rosalind Franklin University for $56,700 for "Characterization and Optimization of Small Molecule Modulators of SMN2 Exon Splicing". 12) In 2009, to Paratek Pharmaceuticals for $20,000 for "Tetracycline Compounds as SMN2 Splicing Modifiers for the Treatment of SMA". Total Funding for the Tetracycline Program of $1,791,400.
| 
